G-SCF-mobilized PBSC (GPB) grafts have a higher cell dose and somewhat more committed progenitor cells than steady-state BM (SBM), resulting in faster engraftment and faster immunological reconstitution. On the other hand, transplant related mortality (TRM), disease-free survival (DFS) and overall survival (OS) are similar both for PB and for BM. In contrast to SBM, G-CSF-primed BM (GBM) grafts stimulate HSC proliferation, increasing cell dose and thus resulting in faster engraftment because of higher cell dose infused, or because of treatment with G-CSF. Furthermore, GBM may induce tolerance and functional modulations in donor hematopoiesis and immunity, further reducing GVHD incidence, which is already lower with SBM compared with GPB grafts. Overall, a growing body of clinical evidence suggests that GBM transplants may share the advantages of GPB transplantations, without the associated increased risk of GVHD, and might be an attractive graft source for allogeneic SCTs.
INTRODUCTION
Allogeneic hematopoietic SCT (allo-HSCT) is a potentially curative treatment for hematological malignancies and blood diseases. 1 As for the HSC grafts, historically autologous and allogeneic transplantations were carried out with BM grafts. Nowadays, most autologous and about 70% of allogeneic transplants are performed using G-CSF-mobilized PBSCs (GPB). 2 In the autologous transplant setting, data suggest that steady-state PBSCs have no better engraftment potential than steady-state BM (SBM). [3] [4] [5] Likewise, several other reports have demonstrated that G-CSF-primed BM (GBM) induces an engraftment comparable to that of GPB, is more effective than unprimed BM and can be safely used in patients submitted to autologous transplantation. [6] [7] [8] [9] [10] [11] However, autologous transplantation is not the best model system for verifying the validity of this hypothesis because of prior chemotherapy and the effects of different transplant preparative regimens. 4, [12] [13] [14] In the allogeneic transplant setting GPB has some advantages compared with SBM mainly because of a higher cell dose, and somewhat more committed progenitor cells than those in the BM, resulting in faster neutrophil and platelet engraftment (3-4 days) and somewhat faster immunological reconstitution. [15] [16] [17] [18] [19] [20] [21] On the other hand, transplant related mortality (TRM), disease-free survival (DFS) and overall survival (OS) are similar for the two HSC sources, and their effects on survival depend on GVHD severity, sensitivity to immunosuppressant treatment, disease type and success of the GVL effect. [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] The numbers of HSCs and other immune effectors in the graft including natural killer and cytotoxic T cells are of major importance for the patient receiving it, as it influences the development and severity of GVHD on one side-the major complication of allo-HSCT-and the failure or success of the transplantation on the other side. [39] [40] [41] Regarding the donor, the potential benefit of GPB donation is avoidance of BM harvesting induced anesthesia, and prolonged bone pain. 42 However, GPB stem cell harvesting contains a risk of poor progenitor cell mobilization (collection of o 2 × 10 6 /kg CD34+ cells), whereas other adverse events are similar in both options. [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] It is now generally accepted that G-CSF mobilization is a critical process, as it promotes cell cycling of multipotent hematopoietic progenitor cells and increases their numbers in the grafts. Furthermore, it alters the proportion of relevant cell populations and their activation state in the BM and the PB, inducing functional modulations in donor hematopoiesis and immune system. [56] [57] [58] [59] [60] [61] Of note also is that no long-term effects or definite link to leukemogenesis have been shown to be associated with short-term G-CSF administration. [62] [63] [64] [65] Indeed, after G-CSF administration in BM, several effects on the BM composition are noticed. The expression of adhesion molecules involved in GVHD pathogenesis (by modulating T-cell migration and homing) decreases. 59, 66 The numbers of immunosuppressive or immunomodulatory MSCs, which are not found in the PB progenitor cell collections, and improve GVHD in experimental and clinical models, increase. 59, 67, 68 The nucleated cells and monocytes are many times fewer in GBM than in GPB. 69 In accordance, the quantities of IL-4 and IFN-γ secreted by GPB T cells are 4.5-and 8.5-fold higher, respectively, and the ratio of anti-inflammatory IL-4/proinflammatory IFN-γ is significantly lower in GPB than in GBM. 69 Also, the dendritic cells (DC1 and DC2) are respectively, 11-and 7-fold higher in GPB than those in GBM. However, the DC2/T-lymphocyte ratio is significantly lower in GPB than in GBM. (The DC2 subgroup induces naive T-cell differentiation to the Th2 phenotype.) 59, 69 As a result, it has been suggested that G-CSF can polarize T cells from Th1 to Th2 phenotype, and induce BM T-cell hyporesponsiveness.
G-CSF mobilization seems also to modulate CD4+/CD25+/FoxP3 + regulatory T-cell (Tregs) activity and to promote their expansion in donors and recipients. Regulatory T cells temper T-cell CD8+ alloreactivity and are involved in the induction and maintenance of tolerance without impairment of GVL effect. Among immune effectors contained in mobilized allograft, natural killer cells also have a key role. They have been recognized to carry strong GVL power without inducing GVHD in T-cell-depleted haploidentical SCT, and their infusion within the graft provides both anti-leukemic and anti-viral activity in the early post transplant period. 69, 70 Therefore, in contrast to SBM grafts, GBM grafts may stimulate proliferation of HSCs and progenitor cells, increasing the cell dose and resulting in faster engraftment due either to the higher cell dose infused including committed precursors or to the G-CSF administration itself (regardless of the stem cell source). Furthermore, GBM may induce tolerance and functional modulations of donor hematopoiesis and immune system. This would lead to lower immunogenicity and T-cell alloreactivity, reducing the GVHD incidence in allogenic transplantation both from HLA-identical and haploidentical sibling donors.
On the other hand, it should be acknowledged that the published experience with GBM consists of multiple small, primarily retrospective studies, with a heterogeneous group of patients. More specifically, the different doses and duration of G-CSF administration, the different diseases and disease status at transplantation and the different conditioning regimens and GVHD prophylaxis used in the studies limit the ability for firm conclusions.
Overall, a growing body of clinical evidence (Tables 1 and 2 ) suggests that GBM transplants share the advantages of GPB transplantations, without the associated increased risk of GVHD. The same multiple small reports suggest that the use of GBM grafts, in G-CSF daily doses of 3-10 μg/kg and with 2-10 days of administration, is safe, feasible and might serve as an attractive stem cell source in the allo-HSCT.
GBM FROM HLA-IDENTICAL SIBLING DONORS
In summary, the use of GBM grafts in comparison with SBM or GPB grafts in HLA-identical SCT is either better or similar. Comparison between GBM and SBM recipients demonstrated faster neutrophil and platelet engraftment for the GBM recipients, whereas no differences were found regarding acute GVHD (aGVHD) incidence, relapse probability, OS and DFS (Table 1) . Comparison between GBM and GPB recipients demonstrated that GVHD incidence was significantly lower in the GBM group, whereas neutrophil and platelet engraftment, and the OS were similar.
GBM vs SBM Based on the above background, Isola et al. 71 administered GBM grafts to 17 patients (10 μg/kg per day G-CSF for 2 days) and compared the outcome with 112 center historical controls demonstrated in two studies (10 μg/kg per day G-CSF for 2 days, and 3-4 μg/kg per day G-CSF for 7 days, respectively) a faster neutrophil and platelet engraftment with GBM grafts, which was attributed to higher CD34+ cell numbers. GBM grafts showed a trend for lower chronic GVHD (cGVHD) incidence, whereas the relapse incidence and the OS were similar for both methods. 73, 74 Lastly, in a three-arm study by Ostronoff et al. 75 comparison between the results of 38 patients who received GBM (5 μg/kg per day G-CSF for 5 days) and SBM historical patient data showed similar platelet engraftment and faster neutrophil engraftment for GBM grafts. However, aGVHD and cGVHD were similar.
GBM vs GPB Somewhat contrarily, comparison in the three-arm study by Ostronoff et al. 75 with the GPB historical data revealed similar times for neutrophil engraftment for GBM and GPB, but a faster platelet engraftment for GPB. The cumulative incidence of refractory aGVHD and extensive cGVHD was significantly higher for GPB. 75 In their two-arm study with GBM and GPB transplant patients (10 μg/kg per day G-CSF for 4 days), Serody et al. 76 also reported similar neutrophil engraftment for GBM patients and SBM published historical data, with a trend toward faster platelet engraftment and lower aGVHD and chronic GVHD for GBM. Notably, in the Australian prospective trial, 57 consecutive patients were randomized to GBM (28 patients) and GPB (29 patients), after receiving 10 μg/kg per day G-CSF for 5 days. Patients in the GPB group received threefold more CD34+ cells and ninefold more CD3+ cells than patients in the GBM group. The median times to neutrophil and platelet engraftment were comparable. The cumulative incidence of refractory aGVHD and extensive cGVHD was significantly higher for the GPB group. The authors concluded that GBM compared with GPB graft resulted in less severe aGVHD and less subsequent cGVHD. Relapse rate and OS were the same. 77 In another two-arm study, Elfenbein et al. 56 compared GBM grafts in 11 patients undergoing allo-SCT with GPB used in 18 patients (10 μg/kg per day G-CSF for 3 days). GBM grafts engrafted just as rapidly as GPB.
GBM+GPB vs GPB Lastly, in a recent retrospective two-arm study, the allo-HSCT outcomes for 98 acute leukemia patients were examined (65 patients received combined GBM and GPB grafts, and 33 patients received GPB-only grafts). The G-CSF dose for donor priming was 5 μg/kg per day for 5 days. Neutrophil and platelet engraftment, and grade 2-4 aGVHD and cGVHD cumulative incidences were similar. However, grade 3-4 aGVHD incidences, and the 5-year probability of leukemia-free survival were significantly better in the combined GBM and GPB group. 78 GBM in the pediatric setting In the pediatric setting, GBM collection is reported to be safe and to result in high CD34+ cell doses, facilitating allo-HSCT engraftment, without increasing aGVHD or cGVHD risk, even for smaller and heavier donors/recipients. In a prospective multicenter trial in children receiving GBM (5 μg/kg per day G-CSF for 5 days), the number of the CD34+ cells collected and infused was high, whereas aGVHD and cGVHD incidence was regular. The median time of neutrophil and platelet engraftment was 19 and 20 days, respectively. 79 Similarly, in another trial with smaller donors, GBM (10 μg/kg per day G-CSF for 2 days) allowed successful engraftment, providing a valuable source option. 80 GBM FROM MISMATCHED/HAPLOIDENTICAL FAMILY DONOR HLA-identical SCT is the preferred choice for allo-HSCT. However, only 25-30% of eligible patients have such a donor and alternative Abbreviations: d = day; DFS = disease-free survival; GBM = G-CSF-primed BM; GPB = G-SCF-mobilized PBSC; yr = years.
G-CSF-primed BM in allogeneic transplantation I Pessach et al options can be matched unrelated donors, unrelated umbilical cord blood and full haplotype-mismatched related donors. [81] [82] [83] [84] [85] [86] As virtually all patients have an immediately available full haplotypemismatched related donor, this donor source has been the alternative option for several reports on GBM (Table 2) . 87 In a single-arm study by Huang et al., 88, 89 171 patients received GBM combined with GPB (5 μg/kg per day G-CSF for 5-6 days) from haplotype-mismatched family donors. All patients achieved hematopoietic recovery after transplantation, rapid neutrophil and platelet engraftment and low cumulative incidence of grade 3-4 aGVHD and extensive cGVHD. Therefore, it was concluded and confirmed by the same team in another study of 250 patients that combined GBM with GPB SCT from haplotype-mismatched family donors results in a high rate of engraftment and an incidence of GVHD, similar to HLA-identical allo-HSCT. 88, 89 Similar results were also reported in 36 myelodysplastic syndrome high-risk/RAEB-t (refractory anemia with excess blasts in transformation) patients who underwent transplantation from combined GBM with GPB (5 μg/kg per day G-CSF for 4-5 days) haplotype-mismatched sibling donors. 90 Rapid and sustained engraftment, without significant increase of GVHD, was also reported in 29 patients with combined GBM with GPB by Wang et al. 91 The same team further confirmed their findings in another one-arm study of 756 patients, who received unmanipulated combined GBM and GPB (5 μg/kg per day G-CSF for 6 days). In that study, the median time for neutrophil and platelet engraftment was 13 and 16 days, respectively. At 100 days after transplant, the cumulative incidence of grade 2-4 and 3-4 aGVHD was 43% and 14% respectively. The total and extensive cGVHD were 53% and 23%, respectively, at 2 years after transplantation. The 3-year TRM was 18%. The 2-year probability of leukemia-free survival and relapse rates were 68% and 15% for standard risk patients, and 49% and 26% for high-risk patients, respectively. 92 An additional two-arm study reported 14 high-risk acute leukemia patients who received GPB, in comparison with 109 high-risk acute leukemia patients who received combined GBM and GPB (5 μg/kg per day G-CSF for 5-6 days). The cumulative myeloid engraftment tendency and the 2-year TRM were significantly lower and higher in GPB group, respectively. For the GPB group alone, non-statistically significant lower cumulative incidence of grades 2-4 aGVHD, lower rates of OS and DFS and similar rates of 2-year relapse were found as compared with combined GBM with GPB transplantation. The authors concluded that GPB transplantation compared with combined GBM with GPB transplantation is potentially inferior in haploidentical settings. 93 On the other hand, in another two-arm study, 80 patients with high-risk hematological malignancies who received GBM alone (4 μg/kg per day G-CSF for 7 days) from haploidentical sibling donors were compared with 250 patients of the 2009 Beijing study who received combined GBM with GPB. 89, 94 A median of 2 × 10 6 / kg CD34+ cells were infused and neutrophil and platelet engraftment were 21 and 28 days, respectively. The cumulative incidence of aGVHD and cGVHD was significantly lower in the GBM group. In this context, it was concluded that GBM compared with combined GBM with GPB resulted in better outcomes, and therefore GBM-unmanipulated transplantation represents a valid alternative for high-risk hematological patients lacking an HLAidentical donor. 94 Concerning GBM alone, in a report of 15 patients with high-risk leukemia, who underwent GBM haploidentical transplantation (3-4 μg/kg per day G-CSF for 7 days), neutrophil and platelet engraftment median time was 19 and 21 days, respectively. G-CSF priming significantly increased the CD34+ cells and aGVHD incidence in GBM transplants compared with SBM published historical data was lower. Therefore, it was concluded that GBM from haploidentical-mismatched sibling donors can be an excellent alternative for the treatment of high-risk hematological patients lacking matched donors. 95 Similar conclusions were also reported for 45 patients with high-risk AML, who received unmanipulated GBM from haploidentical sibling donors. 96 
CONCLUSION
In summary, GBM harvesting appears to be as safe as GPB or SBM harvesting with no potential additional risk or side effects to the donors. GBM in comparison with SBM induces faster engraftment and comparable GVHD, whereas in comparison with GPB collection, it induces comparable median time of engraftment and less GVHD. The GBM appears to be an excellent alternative with regard to GPB 'poor mobilizers'. Most importantly, GBM could be an excellent option in mismatch settings. It induces functional changes in donor hematopoiesis and immune system, resulting in more hyporesponsive T cells, decreased alloreactivity between the host and the donor cells after transplantation, less GVHD and better tolerance. As to expense, GBM has increased cost because of the G-CSF administration to donors for mobilization. On the other hand, patient cost could be decreased by shortened neutropenic period and need for G-CSF administration till myeloid engraftment. All data available from HLA-identical and haploidenticalmismatched sibling donor transplantations relate engraftment outcome to G-CSF administration before collection, rather than the anatomic source of HSCs, and indicate that the use of GBM transplantation is safe and feasible. Keeping in mind that the published experience with GBM so far is limited, we believe that the G-CSF-primed BM should be explored as an option in HLAidentical unrelated transplant settings, as GBM might be advantageous over GPB or traditional untreated SBM.
